Credit: Cell Reports Medicine (2024). DOI: 10.1016/j.xcrm.2024.101606 Leptomeningeal disease is a rare but lethal complication faced by late-stage melanoma patients. It occurs when cancer cells spread to the membranes covering the brain and spinal cord, or the leptomeninges. This condition, which affects 5% to 8% of melanoma patients, often leads to rapid deterioration and is notoriously resistant to therapies. However, a new Moffitt Cancer Center study, published in Cell Reports Medicine, uncovers the mechanisms that drive this drug resistance, offering new avenues for potential treatments. Moffitt researchers analyzed tissue specimens Read More